GGrantIndex
← Leaderboards

Edgar A Deyoe

Medical College Of Wisconsin

$8,586,984
Attributed
$10,376,600
Total exposure
15
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY200518
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$10,376,600 · 15

By mechanism

R01$5,035,378 · 4
R42$3,257,806 · 2
T32$910,780 · 1
R41$650,638 · 3
P01$261,726 · 1
M01$260,272 · 4

Top collaborators

Most similar at Medical College Of Wisconsin

Same institution · by research overlap

Others in their field

Top investigators on “Functional Magnetic Resonance Imaging

Research focus

Functional Magnetic Resonance ImagingBrain MappingVisual CortexClinical ResearchNeuroimagingHuman SubjectVisual PerceptionBioimaging /Biomedical ImagingTechnologyBaseReportingSignal TransductionBlindnessLinkPsychophysicsBehaviorImageMapsBehavioral /Social Science Research TagNeural Information ProcessingAttentionAdverse EffectsBrain NeoplasmsAlgorithms

Grant awards (36)

Retinal Versus Cortical Contributions to Vision Loss in Albinism$486,022
R01 · FY2018 · EY
Neuroimaging tools for presurgical brain mapping$498,680
R42 · FY2017 · CA · contact PI
Retinal Versus Cortical Contributions to Vision Loss in Albinism$486,022
R01 · FY2017 · EY
Neuroimaging tools for presurgical brain mapping$537,693
R42 · FY2016 · CA · contact PI
Retinal Versus Cortical Contributions to Vision Loss in Albinism$486,022
R01 · FY2016 · EY
Neuroimaging tools for presurgical brain mapping$552,991
R42 · FY2015 · CA · contact PI
Retinal Versus Cortical Contributions to Vision Loss in Albinism$531,802
R01 · FY2015 · EY
Presurgical brain mapping with functional connectivity MRI$277,720
R41 · FY2013 · NS · contact PI
Neuroimaging tools for presurgical brain mapping$272,918
R41 · FY2013 · CA · contact PI
Neuroimaging Aids for Treatment of CNS Vision Pathology$539,858
R42 · FY2011 · CA · contact PI
Neuroimaging Aids for Treatment of CNS Vision Pathology$533,850
R42 · FY2010 · CA · contact PI
Neuroimaging Aids for Treatment of CNS Vision Pathology$594,734
R42 · FY2009 · CA · contact PI
Training in Functional Neuroimaging$169,061
T32 · FY2007 · MH · contact PI
Functional NeuroImaging of Visual Cortex$366,188
R01 · FY2006 · EB · contact PI
Training in Functional Neuroimaging$161,063
T32 · FY2006 · MH · contact PI
Neuroimaging Aids for Treatment of CNS Vision Pathology$100,000
R41 · FY2006 · CA · contact PI
NEUROIMAGING TOOLS FOR ASSESSING VISUAL SYSTEM PATHOLOGY$42,469
M01 · FY2006 · RR · contact PI
FUNCTIONAL MAPPING OF HUMAN VISUAL CORTEX$40,538
M01 · FY2006 · RR · contact PI
Functional NeuroImaging of Visual Cortex$375,000
R01 · FY2005 · EB
Training in Functional Neuroimaging$194,932
T32 · FY2005 · MH
FUNCTIONAL MAPPING OF HUMAN VISUAL CORTEX$46,206
M01 · FY2005 · RR
NEUROIMAGING TOOLS FOR ASSESSING VISUAL SYSTEM PATHOLOGY$44,515
M01 · FY2005 · RR
Functional NeuroImaging of Visual Cortex$375,000
R01 · FY2004 · EB
Neuroimaging Tools for Assessing Visual System Pathology$295,634
R01 · FY2004 · EY
Training in Functional Neuroimaging$193,670
T32 · FY2004 · MH
Functional Mapping of Human Visual Cortex$48,585
M01 · FY2004 · RR
Neuroimaging Tools for Assessing Visual System Pathology$37,959
M01 · FY2004 · RR
Functional NeuroImaging of Visual Cortex$375,000
R01 · FY2003 · EB
Neuroimaging Tools for Assessing Visual System Pathology$287,741
R01 · FY2003 · EY
Training in Functional Neuroimaging$192,054
T32 · FY2003 · MH
Functional NeuroImaging of Visual Cortex$364,440
R01 · FY2002 · EB
Neuroimaging Tools for Assessing Visual System Pathology$356,326
R01 · FY2002 · EY
Polymodal sensory and attentional interaction in human cerebral cortex$0
P01 · FY2002 · MH
Polymodal sensory and attentional interaction in human cerebral cortex$0
P01 · FY2001 · MH
Polymodal sensory and attentional interaction in human cerebral cortex$261,726
P01 · FY2000 · MH
FUNCTIONAL NEUROIMAGING OF HUMAN VISUAL CORTEX$250,181
R01 · FY2000 · EY